Ensysce Biosciences (ENSC) Competitors

$0.34 -0.04 (-10.47%)

As of 11:08 AM Eastern

ENSC vs. HOOK, PASG, CYCN, HOTH, and CLRB

Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include HOOKIPA Pharma (HOOK), Passage Bio (PASG), Cyclerion Therapeutics (CYCN), Hoth Therapeutics (HOTH), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry.

How does Ensysce Biosciences compare to HOOKIPA Pharma?

HOOKIPA Pharma (NASDAQ:HOOK) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

HOOKIPA Pharma has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Ensysce Biosciences has a net margin of -200.87% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%
Ensysce Biosciences	-200.87%	-426.62%	-195.53%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Ensysce Biosciences had 2 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 2 mentions for Ensysce Biosciences and 0 mentions for HOOKIPA Pharma. Ensysce Biosciences' average media sentiment score of 0.63 beat HOOKIPA Pharma's score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
HOOKIPA Pharma	Neutral
Ensysce Biosciences	Positive

Ensysce Biosciences has lower revenue, but higher earnings than HOOKIPA Pharma. HOOKIPA Pharma is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HOOKIPA Pharma	$9.35M	1.56	-$43.50M	-$3.54	N/A
Ensysce Biosciences	$5.07M	0.63	-$10.18M	-$4.22	N/A

63.9% of HOOKIPA Pharma shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 3.3% of HOOKIPA Pharma shares are owned by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

HOOKIPA Pharma and Ensysce Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Ensysce Biosciences compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Passage Bio has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Passage Bio has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -200.87%. Passage Bio's return on equity of -135.04% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-135.04%	-60.37%
Ensysce Biosciences	-200.87%	-426.62%	-195.53%

In the previous week, Passage Bio had 2 more articles in the media than Ensysce Biosciences. MarketBeat recorded 4 mentions for Passage Bio and 2 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.63 beat Passage Bio's score of 0.29 indicating that Ensysce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ensysce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ensysce Biosciences has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$14.48	N/A
Ensysce Biosciences	$5.07M	0.63	-$10.18M	-$4.22	N/A

Passage Bio currently has a consensus target price of $13.25, indicating a potential upside of 180.42%. Given Passage Bio's stronger consensus rating and higher probable upside, analysts clearly believe Passage Bio is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Passage Bio beats Ensysce Biosciences on 10 of the 15 factors compared between the two stocks.

How does Ensysce Biosciences compare to Cyclerion Therapeutics?

Ensysce Biosciences (NASDAQ:ENSC) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Ensysce Biosciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Cyclerion Therapeutics has a net margin of -170.11% compared to Ensysce Biosciences' net margin of -200.87%. Cyclerion Therapeutics' return on equity of -39.23% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-200.87%	-426.62%	-195.53%
Cyclerion Therapeutics	-170.11%	-39.23%	-35.62%

In the previous week, Ensysce Biosciences and Ensysce Biosciences both had 2 articles in the media. Cyclerion Therapeutics' average media sentiment score of 1.43 beat Ensysce Biosciences' score of 0.63 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ensysce Biosciences	Positive
Cyclerion Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cyclerion Therapeutics has lower revenue, but higher earnings than Ensysce Biosciences. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.63	-$10.18M	-$4.22	N/A
Cyclerion Therapeutics	$2.07M	6.54	-$3.53M	-$1.16	N/A

Summary

Cyclerion Therapeutics beats Ensysce Biosciences on 10 of the 12 factors compared between the two stocks.

How does Ensysce Biosciences compare to Hoth Therapeutics?

Hoth Therapeutics (NASDAQ:HOTH) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Hoth Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Hoth Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 622.54%. Given Hoth Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Hoth Therapeutics is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hoth Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ensysce Biosciences has higher revenue and earnings than Hoth Therapeutics. Hoth Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hoth Therapeutics	N/A	N/A	-$12.47M	-$0.90	N/A
Ensysce Biosciences	$5.07M	0.63	-$10.18M	-$4.22	N/A

7.1% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 6.9% of Hoth Therapeutics shares are held by company insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Hoth Therapeutics had 2 more articles in the media than Ensysce Biosciences. MarketBeat recorded 4 mentions for Hoth Therapeutics and 2 mentions for Ensysce Biosciences. Hoth Therapeutics' average media sentiment score of 0.72 beat Ensysce Biosciences' score of 0.63 indicating that Hoth Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hoth Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ensysce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hoth Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -200.87%. Hoth Therapeutics' return on equity of -139.84% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hoth Therapeutics	N/A	-139.84%	-126.88%
Ensysce Biosciences	-200.87%	-426.62%	-195.53%

Summary

Hoth Therapeutics beats Ensysce Biosciences on 11 of the 15 factors compared between the two stocks.

How does Ensysce Biosciences compare to Cellectar Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Cellectar Biosciences had 7 more articles in the media than Ensysce Biosciences. MarketBeat recorded 9 mentions for Cellectar Biosciences and 2 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.63 beat Cellectar Biosciences' score of 0.40 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ensysce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cellectar Biosciences has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -200.87%. Cellectar Biosciences' return on equity of -298.05% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-200.87%	-426.62%	-195.53%
Cellectar Biosciences	N/A	-298.05%	-144.59%

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ensysce Biosciences has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 274.79%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Ensysce Biosciences has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.63	-$10.18M	-$4.22	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$9.53	N/A

Summary

Cellectar Biosciences beats Ensysce Biosciences on 9 of the 15 factors compared between the two stocks.

Get Ensysce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENSC vs. The Competition

Export

Metric	Ensysce Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.21M	$3.41B	$6.24B	$12.14B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-0.08	15.32	20.67	25.38
Price / Sales	0.63	304.64	547.41	75.53
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	0.54	6.83	9.59	6.65
Net Income	-$10.18M	$24.11M	$3.54B	$333.19M
7 Day Performance	-14.50%	-1.58%	-0.45%	-0.55%
1 Month Performance	-26.37%	3.84%	5.68%	7.66%
1 Year Performance	-84.38%	70.95%	38.47%	35.65%

Ensysce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENSC Ensysce Biosciences	1.2581 of 5 stars	$0.34 -10.5%	N/A	-82.4%	$3.21M	$5.07M	N/A	10	News Coverage Gap Down
HOOK HOOKIPA Pharma	N/A	$1.19 +0.8%	N/A	-9.2%	$14.67M	$9.35M	N/A	160
PASG Passage Bio	3.3447 of 5 stars	$4.27 -6.6%	$13.25 +210.3%	-33.2%	$13.70M	N/A	N/A	130	Earnings Report Short Interest Increase
CYCN Cyclerion Therapeutics	1.3792 of 5 stars	$3.15 -3.4%	N/A	-2.7%	$13.64M	$2.07M	N/A	30	Positive News Upcoming Earnings Short Interest Decrease Gap Down
HOTH Hoth Therapeutics	2.7095 of 5 stars	$0.71 +0.1%	$5.00 +604.2%	-30.7%	$13.58M	N/A	N/A	4	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENSC) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ensysce Biosciences (ENSC) Competitors

ENSC vs. HOOK, PASG, CYCN, HOTH, and CLRB

How does Ensysce Biosciences compare to HOOKIPA Pharma?

Summary

How does Ensysce Biosciences compare to Passage Bio?

Summary

How does Ensysce Biosciences compare to Cyclerion Therapeutics?

Summary

How does Ensysce Biosciences compare to Hoth Therapeutics?

Summary

How does Ensysce Biosciences compare to Cellectar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ensysce Biosciences (ENSC) Competitors

ENSC vs. HOOK, PASG, CYCN, HOTH, and CLRB

How does Ensysce Biosciences compare to HOOKIPA Pharma?

Which has more volatility & risk, HOOK or ENSC?

Is HOOK or ENSC more profitable?

Do analysts prefer HOOK or ENSC?

Does the media refer more to HOOK or ENSC?

Which has stronger earnings & valuation, HOOK or ENSC?

Do insiders & institutionals believe in HOOK or ENSC?

Summary

How does Ensysce Biosciences compare to Passage Bio?

Which has more risk & volatility, PASG or ENSC?

Is PASG or ENSC more profitable?

Does the media refer more to PASG or ENSC?

Do insiders & institutionals believe in PASG or ENSC?

Which has higher earnings and valuation, PASG or ENSC?

Do analysts rate PASG or ENSC?

Summary

How does Ensysce Biosciences compare to Cyclerion Therapeutics?

Which has more risk and volatility, ENSC or CYCN?

Is ENSC or CYCN more profitable?

Does the media prefer ENSC or CYCN?

Do analysts prefer ENSC or CYCN?

Do institutionals and insiders believe in ENSC or CYCN?

Which has stronger earnings and valuation, ENSC or CYCN?

Summary

How does Ensysce Biosciences compare to Hoth Therapeutics?

Which has more risk & volatility, HOTH or ENSC?

Do analysts recommend HOTH or ENSC?

Which has stronger earnings & valuation, HOTH or ENSC?

Do insiders and institutionals believe in HOTH or ENSC?

Does the media favor HOTH or ENSC?

Is HOTH or ENSC more profitable?

Summary

How does Ensysce Biosciences compare to Cellectar Biosciences?

Does the media favor ENSC or CLRB?

Is ENSC or CLRB more profitable?

Do institutionals and insiders believe in ENSC or CLRB?

Which has more volatility & risk, ENSC or CLRB?

Do analysts rate ENSC or CLRB?

Which has higher earnings & valuation, ENSC or CLRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools